Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy.
Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.
Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -1.96 Decreased by -30.57% | - |
| Mar 17, 25 | -1.96 Increased by +14.78% | -1.39 Decreased by -41.52% |
| Nov 7, 24 | -1.30 Decreased by -293.94% | -1.31 Increased by +0.76% |
| Aug 12, 24 | -0.89 Decreased by -187.10% | -1.47 Increased by +39.46% |
| May 9, 24 | -1.50 Decreased by -417.24% | -1.40 Decreased by -7.14% |
| Mar 18, 24 | -2.30 Decreased by -596.97% | -3.37 Increased by +31.75% |
| Nov 9, 23 | -0.33 Increased by +17.50% | -0.32 Decreased by -3.13% |
| Aug 10, 23 | -0.31 Increased by +29.55% | -0.33 Increased by +6.06% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | -3.60 M Decreased by N/A% | -60.53 M Decreased by -144.20% | Increased by +1.68 K% Decreased by N/A% |
| Dec 31, 24 | 0.00 Increased by +100.00% | -60.53 M Decreased by -155.25% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 1.00 M Increased by +N/A% | -27.13 M Increased by +17.49% | Decreased by -2.71 K% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -18.48 M Increased by +41.36% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -24.79 M Increased by +14.69% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | -3.60 M Decreased by N/A% | -23.71 M Increased by +27.56% | Increased by +658.72% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -32.88 M Increased by +18.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -31.51 M Increased by +28.00% | Decreased by N/A% Decreased by N/A% |